Could inhibiting both HDAC and PD-1 improve I-O treatments? by Arlene Weintraub Monday, June 24, 2019 OnKure's HDAC inhibitor overcame resistance to anti-PD-1 therapy in mouse models of B-cell lymphoma, University of Colorado researchers found.
Viracta's combo garners high response in EBV-linked lymphoma by Arlene Weintraub Monday, June 3, 2019 A combination of Viracta Therapeutics' nanatinostat and an antiviral drug produced a 58% response rate in an early trial.
Xynomic preps broad push for HDAC cancer drug by Phil Taylor Friday, June 1, 2018 U.S.-China biotech Xynomic Pharma has raised additional funding to take an HDAC inhibitor in-licensed last year into seven new cancer trials.
Syndax pals up with Nektar on entinostat combo trial by Phil Taylor Thursday, May 31, 2018 Syndax’s shares slid after an ASCO abstract revealed lackluster data with entinostat, but it's forging ahead with a new combination study with Nektar.
Syndax touts possible biomarker data in HDAC/PD-1 combo in NSCLC by Conor Hale Thursday, May 17, 2018 Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.
